Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual Analogue Scale (VAS) of pain is higher than 40 mm.~* Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year~Exclusion Criteria:~* Malignancy within the past 2 years.~* Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathy pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin 300 mg/day (Type: EXPERIMENTAL): None
- Pregabalin 600 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).